MetLife Investment Management LLC Has $49.43 Million Holdings in Thermo Fisher Scientific Inc. $TMO

MetLife Investment Management LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.9% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 99,340 shares of the medical research company’s stock after selling 1,894 shares during the quarter. MetLife Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $49,432,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Port Capital LLC raised its position in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company’s stock worth $721,000 after purchasing an additional 22 shares during the period. Clark Capital Management Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.5% during the fourth quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company’s stock worth $2,312,000 after purchasing an additional 23 shares during the period. Monograph Wealth Advisors LLC raised its position in shares of Thermo Fisher Scientific by 0.3% during the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company’s stock worth $4,507,000 after purchasing an additional 23 shares during the period. Finally, Intergy Private Wealth LLC raised its position in shares of Thermo Fisher Scientific by 5.8% during the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company’s stock worth $208,000 after purchasing an additional 23 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Argus decreased their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a report on Tuesday, April 29th. Barclays upped their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an “equal weight” rating in a report on Thursday, July 24th. Raymond James Financial reiterated an “outperform” rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Robert W. Baird upped their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Finally, HSBC restated a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $593.00.

Thermo Fisher Scientific Stock Up 3.4%

Shares of NYSE:TMO opened at $500.2380 on Friday. The company has a market capitalization of $188.90 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.67 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business has a fifty day moving average price of $443.02 and a two-hundred day moving average price of $456.60. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the transaction, the chief executive officer owned 115,174 shares of the company’s stock, valued at $52,037,916.68. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,896 shares of company stock valued at $8,593,838 in the last quarter. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.